Valo Therapeutics Aims to Improve Personalized Immunotherapy With a New Tech

by Natalia Honchar    Contributor        Biopharma insight / Biopharma Insights

Disclaimer: All opinions expressed by Contributors are their own and do not represent those of their employers, or
Contributors are fully responsible for assuring they own any required copyright for any content they submit to This website and its owners shall not be liable for neither information and content submitted for publication by Contributors, nor its accuracy.

   1022    Comments 0
Topics: Emerging Technologies   

Valo Therapeutics Oy (ValoTx), the developer of antigen-coated oncolytic viruses and vaccine vectors as therapeutic vaccines against cancer and infectious disease, announced the exclusive licensing of intellectual property rights for the PeptiCHIP technology, developed at the University of Helsinki, Finland. This technology is expected to speed up identification of tumor antigens (including the group of neoantigens) for the development of new cancer immunotherapies using Valo’s existing technologies. 

Cancer immunotherapy is a multi-directional group of approaches which share the same core principle: tumor is destroyed using the forces of the human immune system. Basically, depending on how the immune system is exploited, cancer immunotherapies are divided into active and passive. 

In case of active immunotherapy, the given treatment aims to stimulate the host’s immune system, so to say “teach” what to attack and enhance the attack. This group of approaches includes cancer vaccines, immuno-modulators and check-point inhibitors. Why is it working in case of cancer? Tumors often have a hostile immunosuppressive microenvironment, so without the additional boost -- the immune system is blind and weak around the tumor, but active cancer immunotherapy tries to address this issue. 

On the other hand, during passive cancer immunotherapy the immune agents are given to patients. This strategy works great with CAR-T cells for blood cancers, having already multiple FDA-approved treatments. Also passive immunotherapies include monoclonal antibodies binding cancer cells, and oncolytic viruses. To look into more details for the last mentioned class -- oncolytic viruses, it is also fair to classify them as both passive and active immunotherapy at the same time. 

At first, the tumor is attacked with the specifically targeted viruses, which causes the cancer cells lysis (breakage of the cell membrane). Consequently, this leads to the local inflammation, where the immune cells are recruited to clean up the mess, and to pick up new antigens in the process. So, after being at first the passively acting viruses, they consequently stimulate active immune response. This ambidextrous mechanism of action is an attractive strategy for so-called “cold tumors” -- the ones which can’t be reached with the immune system without specific interventions. 

Continue reading

This content available exclusively for BPT Mebmers

Topics: Emerging Technologies   

Share this:              


There are no comments yet. You can be the first.

Leave a Reply

Your email address will not be published. Required fields are marked *

SHARE Share in Facebook Share in Twitter Share in LinkedIn Send by email